FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
The U.S. Food and Drug Administration said on Friday it has approved Sanofi's blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector, offering multiple ...
Sanofi (SNY) wins FDA approval for Sarclisa Escena, a subcutaneously-delivered version of its multiple myeloma therapy ...
Approval covers all current IV isatuximab indications and introduces the first oncology product labeled for both OBI and manual SC administration. IRAKLIA (NCT05405166) established noninferiority of ...
Subcutaneous isatuximab is now approved with pomalidomide/dexamethasone, carfilzomib/dexamethasone, and bortezomib/lenalidomide/dexamethasone, aligning SC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results